Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Pfizer Japan to Diversify Revenue Streams to Maintain Growth in “Post-Lipitor Era”: President
July 2, 2014
- Sumitomo Dainippon Transfers Marketing Rights to 3 Brands Including Inteban to Teikoku Seiyaku
July 2, 2014
- Sanofi Ties Up with Japanese Bioventure for Development of Transdermal Patch Formulation of Lyxumia
July 2, 2014
- Dr Morich’s 900 Million Yen Exec Pay Highest in Takeda
July 1, 2014
- Sanofi, Takeda Team Up to Raise Awareness of Diabetes
July 1, 2014
- Teijin Licenses ADA Deficiency Treatment from Sigma-Tau Pharma
July 1, 2014
- Gilead Submits NDA for HCV Treatment Sofosbuvir in Japan
July 1, 2014
- RaQualia, Eli Lilly of US Cease Research Collaboration for Analgesics
July 1, 2014
- Takeda CEO Defends Millennium, Nycomed Acquisitions as “Not Failures”
June 30, 2014
- Takeda CEO Counters Opposing Shareholders, Says Mr Weber Most Appropriate to Lead Drug Maker
June 30, 2014
- Astellas, UCB Japan File for Cimzia for Treatment-Naïve RA Patients
June 30, 2014
- Weber Becomes 1st Non-Japanese President of Takeda
June 27, 2014
- Eisai Files World’s 1st NDA for Anticancer Agent Lenvatinib in Japan
June 27, 2014
- BMKK to Begin Third-Party Investigation into Company Involvement in Sprycel Trial
June 26, 2014
- Kyowa Pres. Eyes Excursion into Authorized Generic Territory
June 26, 2014
- X-Linked Hypophosphatemia Treatment Improves Phosphate Metabolism in PI/II Study: Kyowa Kirin
June 26, 2014
- BI Japan Halts Development of Faldaprevir, Calls off Entry into Hepatitis C Field
June 26, 2014
- Nihon Chouzai Reaches Price Settlements with All Wholesalers; Expects to Avoid Reductions in Basic Dispensing Fees
June 25, 2014
- SGLT-2 Inhibitors Vigorously Increase in Anterio’s “Mind Share” Ranking in May
June 25, 2014
- Sanofi-Brand Generics of Diovan, Zometa Hit Shelves in Japan
June 24, 2014
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…